Holen Sie sich die Stockscreener-App
0.8301
8.42%
-0.0799
Schlusskurs vom Vortag:
$0.91
Offen:
$0.93
24-Stunden-Volumen:
208.49K
Relative Volume:
0.56
Marktkapitalisierung:
$73.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.64M
KGV:
-2.6943
EPS:
-0.3081
Netto-Cashflow:
$-12.89M
1W Leistung:
-18.29%
1M Leistung:
-31.69%
6M Leistung:
-56.37%
1J Leistung:
+12.62%
1-Tages-Spanne:
$0.8138
$0.9332
1-Wochen-Bereich:
$0.8138
$1.02
52-Wochen-Spanne:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Firmenname
Citius Oncology Inc
Sektor
Telefon
(908) 967-6677
Adresse
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.8284 | 80.33M | 0 | -23.64M | -12.89M | -0.3081 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
114.90 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.06 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.79 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
535.74 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-23 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-11-27 | Eingeleitet | Maxim Group | Buy |
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - Investing.com Nigeria
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data - TipRanks
Citius reports positive Phase 1 topline: 24% ORR, 48% CBR for LYMPHIR + pembrolizumab in gynecologic cancers - TradingView
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - Barchart.com
Aug EndMonth: Can Citius Oncology Inc lead its sector in growthPortfolio Risk Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Aug Highlights: Does Citius Oncology Inc have strong fundamentalsMarket Risk Analysis & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Finviz
Citius Oncology reports 86% response rate in lymphoma study By Investing.com - Investing.com Canada
Citius Oncology reports 86% response rate in lymphoma study - Investing.com
Citius Oncology, Inc. announces preliminary topline data from its study in high-risk diffuse large B-cell lymphoma patients - Bitget
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Oncology reports 86% ORR and favorable safety for LYMPHIR prior to commercial CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - Barchart.com
Early lymphoma trial tests LYMPHIR before CAR-T, sees 86% response rate - Stock Titan
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat
Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - MSN
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz
New Jersey tax program turns Citius Pharma losses into $3.8M cash - Stock Titan
CTOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Outlook: Can Citius Oncology Inc keep up with sector leadersJuly 2025 Highlights & High Accuracy Buy Signal Tips - baoquankhu1.vn
Aug Selloffs: What are Merus NVs earnings expectationsMarket Weekly Review & Smart Swing Trading Alerts - baoquankhu1.vn
Aug Drivers: Is TCRT stock showing strong momentumMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Is Citius Oncology Inc. stock a contrarian buyTrade Exit Summary & Growth Oriented Trading Recommendations - mfd.ru
Analysts Are Bullish on Top Healthcare Stocks: Citius Oncology (CTOR), Autolus Therapeutics (AUTL) - The Globe and Mail
Aug PreEarnings: Can Citius Oncology Inc lead its sector in growth2025 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Armistice Capital reports 8.08M Citius Oncology (NASDAQ: CTOR) stake - Stock Titan
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt
Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal - Indian Pharma Post
CTOR PE Ratio & Valuation, Is CTOR Overvalued - Intellectia AI
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve
Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates - MarketBeat
Earnings Breakdown: Citius Oncology Q1 - Benzinga
CITIUS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Press Release: Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM) - 富途牛牛
Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI
Citius Oncology Q1 Earnings Summary & Key Takeaways - Benzinga
Citius Oncology and Uniphar sign European distribution deal for Lymphir - Yahoo Finance
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar - Finviz
Citius inks EU distribution agreement for CTCL treatment - The Pharma Letter
Biopharmaceutical company Citius Oncology announced that it has signed an exclusive distribution agreement with Europe's leading healthcare product provider Uniphar, officially expanding the commercialization of its innovative lymphoma therapy Lymphir - Bitget
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire
Citius Oncology (CTOR) Projected to Post Quarterly Earnings on Friday - MarketBeat
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 22.3% in January - MarketBeat
Interleukin-2 (IL-2) Market to Grow Rapidly Over the Next Decade by 2034, DelveInsight Observes | Eisai, Citius Oncology, Corvus Pharmaceuticals, ILTOO Pharma - Barchart.com
CEO Moves: Why is Citius Oncology Inc stock going down2025 Trading Recap & Smart Investment Allocation Insights - baoquankhu1.vn
Decliners Report: Is Citius Oncology Inc undervalued by DCF analysisJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Why Citius Oncology Inc. stock attracts global investorsEarnings Risk Report & Reliable Trade Execution Plans - bollywoodhelpline.com
Finanzdaten der Citius Oncology Inc-Aktie (CTOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
0.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):